News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,748 Results
Type
Article (40955)
Company Profile (267)
Press Release (680516)
Multimedia
Podcasts (84)
Webinars (17)
Section
Business (204677)
Career Advice (2023)
Deals (35536)
Drug Delivery (110)
Drug Development (81398)
Employer Resources (173)
FDA (16410)
Job Trends (14944)
News (346409)
Policy (32726)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2567)
Accelerated approval (32)
Adcomms (24)
Allergies (142)
Alliances (49576)
ALS (169)
Alzheimer's disease (1667)
Antibody-drug conjugate (ADC) (310)
Approvals (16679)
Artificial intelligence (517)
Autoimmune disease (153)
Automation (39)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (189)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (638)
Cancer (4800)
Cardiovascular disease (398)
Career advice (1708)
Career pathing (36)
CAR-T (282)
CDC (44)
Celiac Disease (2)
Cell therapy (743)
Cervical cancer (36)
Clinical research (69570)
Collaboration (1700)
Company closure (4)
Compensation (1157)
Complete response letters (54)
COVID-19 (2711)
CRISPR (89)
C-suite (841)
Cystic fibrosis (143)
Data (6218)
Decentralized trials (2)
Denatured (28)
Depression (131)
Diabetes (500)
Diagnostics (6687)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (253)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (231)
Earnings (90174)
Editorial (57)
Employer branding (21)
Employer resources (152)
Events (117273)
Executive appointments (971)
FDA (19522)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1466)
Gene editing (195)
Generative AI (43)
Gene therapy (595)
GLP-1 (966)
Government (4660)
Grass and pollen (6)
Guidances (383)
Healthcare (18873)
HIV (58)
Huntington's disease (44)
IgA nephropathy (83)
Immunology and inflammation (249)
Immuno-oncology (57)
Indications (110)
Infectious disease (2980)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (248)
Interviews (315)
IPO (16642)
IRA (50)
Job creations (3642)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (85)
Layoffs (546)
Leadership (31)
Legal (7949)
Liver cancer (91)
Longevity (14)
Lung cancer (646)
Lymphoma (376)
Machine learning (42)
Management (59)
Manufacturing (792)
MASH (163)
Medical device (13768)
Medtech (13821)
Mergers & acquisitions (19964)
Metabolic disorders (1266)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (314)
Neuropsychiatric disorders (88)
Neuroscience (2892)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4514)
Now hiring (67)
Obesity (594)
Opinion (259)
Ovarian cancer (166)
Pain (198)
Pancreatic cancer (226)
Parkinson's disease (279)
Partnered (33)
Patents (495)
Patient recruitment (489)
Peanut (56)
People (58867)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21686)
Phase 2 (30616)
Phase 3 (22815)
Pipeline (5270)
Policy (281)
Postmarket research (2564)
Preclinical (9196)
Press Release (64)
Prostate cancer (237)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (832)
Real estate (5954)
Recruiting (70)
Regulatory (24480)
Reports (52)
Research institute (2387)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (148)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (96)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3614)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (1003)
Venture capital (88)
Weight loss (380)
Women's health (91)
Worklife (18)
Date
Today (104)
Last 7 days (609)
Last 30 days (2113)
Last 365 days (29905)
2026 (3420)
2025 (30173)
2024 (35219)
2023 (40082)
2022 (51176)
2021 (55711)
2020 (54085)
2019 (46541)
2018 (35018)
2017 (32125)
2016 (31488)
2015 (37555)
2014 (31318)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27329)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39223)
Australia (6409)
California (11281)
Canada (3285)
China (1099)
Colorado (477)
Connecticut (475)
Delaware (336)
Europe (84517)
Florida (1688)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (859)
India (65)
Indiana (519)
Iowa (22)
Japan (430)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1381)
Massachusetts (8078)
Michigan (324)
Minnesota (628)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2999)
New Mexico (28)
New York (2972)
North Carolina (1449)
North Dakota (8)
Northern California (5513)
Ohio (333)
Oklahoma (21)
Oregon (41)
Pennsylvania (2275)
Puerto Rico (24)
Rhode Island (48)
South America (1108)
South Carolina (66)
South Dakota (1)
Southern California (4389)
Tennessee (174)
Texas (1740)
United States (39974)
Utah (334)
Vermont (1)
Virginia (260)
Washington D.C. (81)
Washington State (918)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
721,748 Results for "exelixis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
October 21, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Exelixis Lays Off 130 as Pennsylvania Site Closes Down
Exelixis is looking at the possibility of relocating some of the eliminated Pennsylvania roles to its headquarters in Alameda, California, according to a company spokesperson.
August 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
February 11, 2026
·
19 min read
Press Releases
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
January 28, 2026
·
1 min read
Press Releases
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
January 7, 2026
·
1 min read
Press Releases
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
January 8, 2026
·
10 min read
Press Releases
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
February 2, 2026
·
7 min read
Press Releases
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
January 12, 2026
·
19 min read
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
December 4, 2025
·
1 min read
1 of 72,175
Next
